|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 283, Issue 38, 26081-26088, September 19, 2008
The Type 2 Inositol (1,4,5)-Trisphosphate (InsP3) Receptor Determines the Sensitivity of InsP3-induced Ca2+ Release to ATP in Pancreatic Acinar Cells*![]() 1 12![]() ![]()
From the
Calcium release through inositol (1,4,5)-trisphosphate receptors (InsP3R) is the primary signal driving digestive enzyme and fluid secretion from pancreatic acinar cells. The type 2 (InsP3R2) and type 3 (InsP3R3) InsP3R are the predominant isoforms expressed in acinar cells and are required for proper exocrine gland function. Both InsP3R2 and InsP3R3 are positively regulated by cytosolic ATP, but InsP3R2 is 10-fold more sensitive than InsP3R3 to this form of modulation. In this study, we examined the role of InsP3R2 in setting the sensitivity of InsP3-induced Ca2+ release (IICR) to ATP in pancreatic acinar cells. IICR was measured in permeabilized acinar cells from wild-type (WT) and InsP3R2 knock-out (KO) mice. ATP augmented IICR from WT pancreatic cells with an EC50 of 38 µM. However, the EC50 was 10-fold higher in acinar cells isolated from InsP3R2-KO mice, indicating a role for InsP3R2 in setting the sensitivity of IICR to ATP. Consistent with this idea, heterologous expression of InsP3R2 in RinM5F cells, which natively express predominately InsP3R3, increased the sensitivity of IICR to ATP. Depletion of ATP attenuated agonist-induced Ca2+ signaling in WT pancreatic acinar cells. This effect was more profound in acinar cells prepared from InsP3R2-KO mice. These data suggest that the sensitivity of IICR to ATP depletion is regulated by the particular complement of InsP3R expressed in an individual cell. The effects of metabolic stress on intracellular Ca2+ signals can therefore be determined by the relative amount of InsP3R2 expressed in cells.
Received for publication, May 30, 2008 , and in revised form, July 21, 2008. * This work was supported, in whole or in part, by National Institutes of Health Training Grant T32-DE07202 from NIDCR (to M. J. B.), National Institutes of Health Grants RO1-DK054568 and RO1-DE016999 (to D. I. Y.), and a National Institutes of Health grant (to J. C). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 Both authors contributed equally to this work. 2 To whom correspondence should be addressed: Dept. of Pharmacology and Physiology, School of Medicine and Dentistry, University of Rochester Medical Center, 601 Elmwood Ave., Box 711, Rochester, NY 14642. Tel.: 585-273-2154; Fax: 585-273-2652; E-mail: Matthew_Betzenhauser{at}urmc.rochester.edu.
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||